E-cadherin is consistently expressed in various epithelial cancers and down-regulation or loss of E-cadherin expression in cancers arising from E-cadherin positive tissues as well as those arising from E-cadherin negative tissues is linked to cancer progression and may reflect tumor dedifferentiation [47,48,49]; thus, studies have indicated that the inactivation of this gene results in larger tumors, higher tumor grades, and an increased risk of metastasis and chemoresistance [47,48,49]. The gene discussed is CDH1; the disease is cancer.